Abstract:L-asparaginase (L-ASP) is one of the key enzymes used in therapeutic applications, particularly to treat Acute Lymphocytic Leukemia (ALL). L-asparagine is a non-essential amino acid, which means that it can be synthesized by the body and is not required to be obtained through the diet. The synthesis of L-asparagine occurs primarily in the liver, but it also takes place in other tissues throughout the body. In contrast, leukemic cells cannot synthesize L-asparagine due the absence of L-asparagine synthetase and should obtain it from circulating sources for protein synthesis and cell division processes to ensure their vital functions. L-ASP catalyzes the deamination process of L-asparagine amino-acid into aspartic acid and ammonia, depriving leukemic cells of asparagine. This leads to decreased protein synthesis and cell division in tumor cells. However, using L-ASP has side effects, such as hypersensitivity or allergic reaction, antigenicity, short half-life, temporary blood clearance, and toxicity. L-ASP immobilization can minimize the side effects of L-ASP by stopping the immune system from attacking non-human enzymes and improving the enzyme's performance. The first strategy includes modification of enzyme structure, such as covalent binding (conjugation), adsorption to the support material and cross-linking of the enzyme. The chemical modification of residues, often nonspecific, changes the enzyme's hydrophobicity and surface charge, lowering the enzyme's activity. Also, the first strategy exposes the enzyme's surface to the environment. This eliminates its performance and does not allow targeted delivery of the enzyme. The second strategy is based on the entrapment of the enzyme inside the protecting structure or encapsulation. This strategy offers the same benefits as the first. Still, it also enables reducing toxicity, prolonging in vivo half-life, enhancing stability and activity, enables a targeted delivery and controlled release of the enzyme. Compared to the first strategy, encapsulation does not modify the chemical structure of the enzyme since L-ASP is only effective against leukemia in its native tetrameric form. This review aims to present state of the art in L-ASP formulations developed for reducing the side effects of L-ASP, focusing on describing improvements in their safety. The primary focus in the field remains to be improving the overall performance of the L-ASP formulations. Almost all encapsulation systems allow reducing immune response due to screening the enzyme from antibodies and prolonging its half-life. However, the enzyme's activity and stability depend on the encapsulation system type. Therefore, the selection of the right encapsulation system is crucial in therapy due to its effect on the performance parameters of the L-ASP. Biodegradable and biocompatible materials, such as chitosan, alginate and liposomes, mainly attract the researcher's interest in enzyme encapsulation. The research trends are also moving towards developing formulations with targeted delivery and increased selectivity.

A Comprehensive Review of L-Asparaginase: Production, Applications and Therapeutic Potential in Cancer Treatment

A comprehensive review on microbial l-asparaginase: Bioprocessing, characterization, and industrial applications

Biotechnological production and practical application of L-asparaginase enzyme

Insights into the Microbial L-Asparaginases: from Production to Practical Applications

Microbial production, molecular modification, and practical application of l-Asparaginase: A review

Production Strategies and Applications of L-asparaginase

Desirable L-asparaginases for treating cancer and current research trends

Production of Chemotherapeutic Enzyme L-asparaginase from a Fungal Source

L-asparaginase: therapeutic use and applications in the food industry – a review

Production of highly cytotoxic and low immunogenic L-asparaginase from Stenotrophomonas maltophilia EMCC2297

Current state of molecular and metabolic strategies for the improvement of L-asparaginase expression in heterologous systems

Isolation of asparaginase-producing microorganisms and evaluation of the enzymatic antitumor activity

Production of Recombinant Human Asparaginase from Escherichia coli under Optimized Fermentation Conditions: Effect of Physicochemical Properties on Enzyme Activity

Screening and Optimization of Process Parameters for the Production of l-asparaginase by Indigenous Fungal-Type Strains

Recent Strategies and Applications for l-Asparaginase Confinement

Optimizing recombinant production of L-asparaginase 1 from Saccharomyces cerevisiae using response surface methodology

L-Asparaginase delivery systems targeted to minimize its side-effects

Development of L-Asparaginase Biobetters: Current Research Status and Review of the Desirable Quality Profiles

Isolation, Identification, and Characterization of L-asparaginase-Producing Human Commensal Bacterial Strains: A Promising Next-Gen Probiotics

Potential L-asparaginase producing E.coli sources among River water and cafeteria sewage: The case of Wabe River and Wolkite University students' cafeteria in Wolkite, Ethiopia.

Studies on nutritional and oxygen requirements for production of L-asparaginase by Enterobacter aerogenes